PolyTherics to Receive Knowledge Transfer Partnership Programme Funding

Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
PolyTherics Limited has announced that the Technology Strategy Board (TSB) had offered The School of Pharmacy, University of London, a Knowledge Transfer Partnership (KTP) grant that will be used to part-fund work being undertaken in collaboration with PolyTherics.
The funding will be used to employ a KTP Associate who will develop and optimize the use of mass spectroscopy to confirm the location of polyethylene (glycol) (PEG) on proteins and peptides that are being developed as long-acting drugs by PolyTherics. The project is scheduled to run for 24 months and the TSB is providing just over £78,000 to support the work.
PolyTherics has substantial expertise in the targeted modification of biologic compounds with therapeutic potential. Through its platform of site specific technologies to conjugate PEG to proteins and peptides, the Company systematically optimizes the performance of biologics for administration as injectable drugs. Its most advanced programme is an interferon alpha PEGylated using its HiPEG™ technology that is being developed as a biobetter medicine. The Company has recently launched a new website which provides the latest information on all its technologies.
Dr Keith Powell, Chief Executive Officer at PolyTherics, commented “We are delighted that The School of Pharmacy has received this funding to support our partnership with them in this challenging project.”
Dr Bill Lindsay, Business Development Manager at the School of Pharmacy, commented “We are very pleased to receive this award which will provide a great opportunity to add to the knowledge base and commercial potential of an area in which PolyTherics is at the forefront.”
The funding will be used to employ a KTP Associate who will develop and optimize the use of mass spectroscopy to confirm the location of polyethylene (glycol) (PEG) on proteins and peptides that are being developed as long-acting drugs by PolyTherics. The project is scheduled to run for 24 months and the TSB is providing just over £78,000 to support the work.
PolyTherics has substantial expertise in the targeted modification of biologic compounds with therapeutic potential. Through its platform of site specific technologies to conjugate PEG to proteins and peptides, the Company systematically optimizes the performance of biologics for administration as injectable drugs. Its most advanced programme is an interferon alpha PEGylated using its HiPEG™ technology that is being developed as a biobetter medicine. The Company has recently launched a new website which provides the latest information on all its technologies.
Dr Keith Powell, Chief Executive Officer at PolyTherics, commented “We are delighted that The School of Pharmacy has received this funding to support our partnership with them in this challenging project.”
Dr Bill Lindsay, Business Development Manager at the School of Pharmacy, commented “We are very pleased to receive this award which will provide a great opportunity to add to the knowledge base and commercial potential of an area in which PolyTherics is at the forefront.”